Erythropoietin-induced, antibody-mediated pure red cell aplasia
- PMID: 16281965
- DOI: 10.1111/j.1365-2362.2005.01536.x
Erythropoietin-induced, antibody-mediated pure red cell aplasia
Abstract
Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients. Eur J Clin Invest 2005; 35 (Suppl. 3): 95-99.
Similar articles
-
Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.Am J Gastroenterol. 2005 Jun;100(6):1415-9. doi: 10.1111/j.1572-0241.2005.41910.x. Am J Gastroenterol. 2005. PMID: 15929778
-
[Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment].Przegl Lek. 2010;67(3):187-91. Przegl Lek. 2010. PMID: 20687383 Review. Polish.
-
Antibody-mediated pure red-cell aplasia (PRCA): the Spanish experience.J Nephrol. 2005 Jul-Aug;18(4):382-7. J Nephrol. 2005. PMID: 16245241
-
Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia.Eur J Haematol. 2004 Dec;73(6):389-96. doi: 10.1111/j.1600-0609.2004.00348.x. Eur J Haematol. 2004. PMID: 15522059 Review.
-
Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.Curr Med Res Opin. 2004 Jan;20(1):83-6. doi: 10.1185/030079903125002702. Curr Med Res Opin. 2004. PMID: 14741076 Review.
Cited by
-
Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances.AAPS PharmSciTech. 2008;9(4):1218-29. doi: 10.1208/s12249-008-9148-3. Epub 2008 Dec 16. AAPS PharmSciTech. 2008. PMID: 19085110 Free PMC article. Review.
-
Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.Drugs. 2007;67(2):175-94. doi: 10.2165/00003495-200767020-00002. Drugs. 2007. PMID: 17284083 Review.
-
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.World J Biol Chem. 2012 Apr 26;3(4):73-92. doi: 10.4331/wjbc.v3.i4.73. World J Biol Chem. 2012. PMID: 22558487 Free PMC article.
-
Pure Red Cell Aplasia Following Interleukin-2 Therapy.J Investig Med High Impact Case Rep. 2016 Apr 11;4(2):2324709616643991. doi: 10.1177/2324709616643991. eCollection 2016 Apr-Jun. J Investig Med High Impact Case Rep. 2016. PMID: 27144182 Free PMC article.
-
Biosimilars: recent developments.Int Urol Nephrol. 2007;39(1):261-6. doi: 10.1007/s11255-006-9167-5. Epub 2007 Feb 27. Int Urol Nephrol. 2007. PMID: 17333516 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources